Drug Profile


Alternative Names: bezafibrate SR + diflunisal IR; CRx-401; Diflunisal/bezafibrate

Latest Information Update: 29 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Antihyperlipidaemics; Antirheumatics; Butyrates; Fibric acid derivatives; Nonsteroidal anti-inflammatories; Salicylates
  • Mechanism of Action Cyclooxygenase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in Canada (PO)
  • 09 Sep 2010 CombinatoRx is now called Zalicus
  • 28 May 2009 Efficacy & adverse events data from a phase IIa trial in Type-2 diabetes released by CombinatoRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top